Companies › Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
1 active drug program in 3 registered trials: 1 Phase 3, 1 Phase 2, 1 Phase 1; Infectious disease; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MK-1406/CD388 Antifungal vaccine candidate (1,3-β-glucan based immunotherapeutic) | – | Phase 3 | Influenza; Healthy Participants | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07300085 | MK-1406/CD388 | Phase 1 | Healthy Participants | Infectious disease | Dec 2026 |
| NCT07159763 | MK-1406/CD388 | Phase 3 | Influenza | Infectious disease | Jun 2027 |
| NCT07225959 | MK-1406/CD388 | Phase 2 | Healthy Participants | Infectious disease | Jul 2027 |
No annotated target.
–
Laboratorio Farmaceutico SIT srl Zero Point Five Therapeutics Lallemand Pharma MicuRx Jiangxi Qingfeng Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.